Figure legends
Figure 1. Behavioral and neurochemical effects of reverse
dialysis of telenzepine in the dopamine-depleted striatum of dyskinetic
rats undergoing microdialysis. Dyskinetic rats were implanted with one
probe in the lesioned dorsolateral striatum and another in ipsilateral
substantia nigra reticulata (SNr). Twenty-four hours later, rats
received an acute challenge with L-DOPA alone (6 mg
kg-1 plus 12 mg kg-1 benserazide,
i.p.) or in combination with telenzepine (100 nM) through the probe.
Telenzepine perfusion started 40 min prior to L-DOPA administration and
continued until the end of experiment. A group treated with telenzepine
alone was also included. ALO AIMs were scored for 1 min every 20 min
over 120 min after L-DOPA administration, then cumulative ALO AIMs
calculated (A). Dialysate samples were collected every 20 min for 120
min after L-DOPA administration, and GABA (B) and glutamate (Glu; C-D)
levels in dialysates were monitored in SNr and striatum. Data are means
± SEM of 8 rats per group. Data were statistically analyzed as
cumulative ALO AIMs score using the Mann-Whitney test (A) or as AUC
values using ANOVA followed by the Newman-Keuls test (B-D).
*p<0.05 different from Ringer + L-DOPA 6 mg
Kg-1; °p<0.05, °°p<0.01, different
from Telenzepine 100 nM + saline.
Figure 2. Behavioral and neurochemical effects of reverse
dialysis of PD-102807 in the dopamine-depleted striatum of dyskinetic
rats undergoing microdialysis. Dyskinetic rats were implanted with one
probe in the lesioned dorsolateral striatum and another in ipsilateral
substantia nigra reticulata (SNr). Twenty-four hours later, rats
received an acute challenge with L-DOPA alone (6 mg
kg-1 plus 12 mg kg-1 benserazide,
i.p.) or in combination with PD-102807 (3 µM) through the probe.
PD-102807 perfusion started 40 min prior to L-DOPA administration and
continued until the end of experiment. A group treated with PD-102807
alone was also included. ALO AIMs were scored for 1 min every 20 min
over 120 min after L-DOPA administration, then cumulative ALO AIMs
calculated (A). Dialysate samples were collected every 20 min for 120
min after L-DOPA administration, and GABA (B) and glutamate (Glu; C-D)
levels in dialysates were monitored in SNr and striatum. Data are means
± SEM of 8 rats per group. Data were statistically analyzed as
cumulative ALO AIMs score using the Mann-Whitney test (A) or as AUC
values using ANOVA followed by the Newman-Keuls test (B-D).
**p<0.01 different from Ringer + L-DOPA 6 mg
Kg-1; °°p<0.01, different from PD-102807 3
µM + saline.
Figure 3. Behavioral and neurochemical effects of reverse
dialysis of tropicamide in the dopamine-depleted striatum of dyskinetic
rats undergoing microdialysis. Dyskinetic rats were implanted with one
probe in the lesioned dorsolateral striatum and another in ipsilateral
substantia nigra reticulata (SNr). Twenty-four hours later, rats
received an acute challenge with L-DOPA alone (6 mg
kg-1 plus 12 mg kg-1 benserazide,
i.p.) or in combination with tropicamide (100 nM) through the probe.
Tropicamide perfusion started 40 min prior to L-DOPA administration and
continued until the end of experiment. A group treated with tropicamide
alone was also included. ALO AIMs were scored for 1 min every 20 min
over 120 min after L-DOPA administration, then cumulative ALO AIMs
calculated (A). Dialysate samples were collected every 20 min for 120
min after L-DOPA administration, and GABA (B) and glutamate (Glu; C-D)
levels in dialysates were monitored in SNr and striatum. Data are means
± SEM of 8 rats per group. Data were statistically analyzed as
cumulative ALO AIMs score using the Mann-Whitney test (A) or as AUC
values using ANOVA followed by the Newman-Keuls test (B-D).
*p<0.05, **p<0.01, different from Ringer + L-DOPA 6
mg Kg-1; °°p<0.01, different from
Tropicamide 100 nM + saline.
Figure 4. Behavioral and neurochemical effects of reverse
dialysis of VU0152100 in the dopamine-depleted striatum of dyskinetic
rats undergoing microdialysis. Dyskinetic rats were implanted with one
probe in the lesioned dorsolateral striatum and another in ipsilateral
substantia nigra reticulata (SNr). Twenty-four hours later, rats
received an acute challenge with L-DOPA alone (6 mg
kg-1 plus 12 mg kg-1 benserazide,
i.p.) or in combination with VU0152100 (100 µM) through the probe.
VU0152100 perfusion started 40 min prior to L-DOPA administration and
continued until the end of experiment. A group treated with VU0152100
alone was also included. ALO AIMs were scored for 1 min every 20 min
over 120 min after L-DOPA administration, then cumulative ALO AIMs
calculated (A). Dialysate samples were collected every 20 min for 120
min after L-DOPA administration, and GABA (B) and glutamate (Glu; C-D)
levels in dialysates were monitored in SNr and striatum. Data are means
± SEM of 8 rats per group. Data were statistically analyzed as
cumulative ALO AIMs score using the Mann-Whitney test (A) or as AUC
values using ANOVA followed by the Newman-Keuls test (B-D).
*p<0.05; **p<0.01 different from Ringer + L-DOPA 6
mg Kg-1; °p<0.05, °°p<0.01,
different from VU0152100 100 µM + saline.
Figure 5. Behavioral and neurochemical effects of reverse
dialysis of AFDX-116 in the dopamine-depleted striatum of dyskinetic
rats undergoing microdialysis. Dyskinetic rats were implanted with one
probe in the lesioned dorsolateral striatum and another in ipsilateral
substantia nigra reticulata (SNr). Twenty-four hours later, rats
received an acute challenge with L-DOPA alone (6 mg
kg-1 plus 12 mg kg-1 benserazide,
i.p.) or in combination with AFDX-116 (200 nM) or AFDX-116 (200 nM) +
PD-102807 (3 µM) through the probe. PD-102807 perfusion started 40 min
prior to L-DOPA administration whereas perfusion with AFDX-116 started
60 min prior to L-DOPA or 20 min prior to PD-102807 and continued until
the end of experiment. A group treated with AFDX-116 alone was also
included. ALO AIMs were scored for 1 min every 20 min over 120 min after
L-DOPA administration, then cumulative ALO AIMs calculated (A).
Dialysate samples were collected every 20 min for 120 min after L-DOPA
administration, and GABA (B) and glutamate (C-D) levels in dialysates
were monitored in striatum and SNr. Data are means ± SEM of 8 rats per
group. Data were statistically analyzed as cumulative ALO AIMs score
using the the Mann-Whitney test (A) or as AUC values using ANOVA
followed by the Newman-Keuls test (B-F). *p<0.05,
**p<0.01 different from Ringer + L-DOPA; #p<0.05
different from PD-102807 3 µM + L-DOPA; °p<0.05;
°°p<0.01 different from VU0152100 100 µM + saline (B-D) or
PD-102807 3 µM + saline (E-F).
Figure 6. Behavioral and neurochemical effects of reverse
dialysis of VU0152100 or PD-102807 in the substantia nigra pars
reticulata (SNr) of dyskinetic rats undergoing microdialysis. Dyskinetic
rats were implanted with one probe in the lesioned dorsolateral striatum
and another in ipsilateral SNr. Twenty-four hours later, rats received
an acute challenge with L-DOPA alone (6 mg kg-1 plus
12 mg kg-1 benserazide, i.p.) or in combination with
VU0152100 (100 µM) or PD-102807 (3 µM) through the nigral probe.
VU0152100 or PD-102807 perfusion started 40 min prior to L-DOPA
administration and continued until the end of experiment. A group
treated with VU0152100 or PD-102807 alone were also included. ALO AIMs
were scored for 1 min every 20 min over 120 min after L-DOPA
administration, then cumulative ALO AIMs calculated (A). Dialysate
samples were collected every 20 min for 120 min after L-DOPA
administration, and GABA (B, E) and glutamate (Glu; B-F) levels in
dialysates were monitored in SNr or striatum. Data are means ± SEM of 8
rats per group. Data were statistically analyzed as cumulative ALO AIMs
score using the Kruskal-Wallis test for non parametric ANOVA followed by
the Dunn test (A) or as AUC values using ANOVA followed by the
Newman-Keuls test (B-F) *p<0.05, **p<0.01 different
from Ringer + L-DOPA; #p<0.05 different from PD-102807 3 µM +
L-DOPA; °p<0.05; °°p<0.01 different from VU0152100
100 µM + saline (B-D) or PD-102807 3 µM + saline (E-F).